{"transactions":[{"id":792764,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2026-05-05T22:21:13.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029."}],"balance_after":110000,"derivative":{"exercise_price":0.29,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792763,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-05-05T22:21:13.000Z","date":"2026-03-01","kind":"other","planned":false,"acquired":false,"shares":900000,"price":0.3,"value":270000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"900,000 warrants to purchase shares of common stock with an exercise price of $0.30, with an issuance date of March 1, 2023, expired on March 1, 2026, without being exercised."}],"balance_after":2700000,"derivative":{"exercise_price":0.3,"exercise_date":"2023-03-01","expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792762,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-05-05T22:21:13.000Z","date":"2026-02-25","kind":"exercise","planned":false,"acquired":false,"shares":1000000,"price":0.2,"value":200000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.2,"exercise_date":"2026-02-25","expiration_date":"2026-02-25","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792761,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-05-05T22:21:13.000Z","date":"2026-02-25","kind":"grant","planned":false,"acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":1000000,"derivative":{"exercise_price":0.2,"exercise_date":"2026-02-25","expiration_date":"2026-02-25","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792760,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-05-05T22:21:13.000Z","date":"2026-02-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2022-09-01","expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792759,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-05-05T22:21:13.000Z","date":"2026-02-25","kind":"grant","planned":false,"acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":1000000,"derivative":{"exercise_price":0.65,"exercise_date":"2026-02-25","expiration_date":"2027-09-01","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792758,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-05-05T22:21:13.000Z","date":"2026-02-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.65,"exercise_date":"2022-09-01","expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792757,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T22:21:13.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":true,"shares":352000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":10391311,"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792756,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series F-2 Stock","published_at":"2026-05-05T22:21:13.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":false,"shares":88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792755,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T22:21:13.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":true,"shares":19038,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.2773."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.2773."}],"balance_after":10039311,"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792754,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T22:21:13.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":true,"shares":1040000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":10020273,"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792753,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series F Stock","published_at":"2026-05-05T22:21:13.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":false,"shares":260,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792752,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T22:21:13.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":true,"shares":56093,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773."}],"balance_after":8980273,"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":792751,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T22:21:13.000Z","date":"2026-02-25","kind":"exercise","planned":false,"acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":8924180,"source":{"system":"sec-edgar","filing":"0001477932-26-002770","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002770/form4.xml","form_type":"4"}},{"id":813840,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53500,"kind":"person","name":"Grujic Alan","position":1,"cik":"0001980904","reported_name":"Grujic Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-04-07T21:10:58.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the award vested on March 10,2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 9, 2029."}],"balance_after":110000,"derivative":{"exercise_price":0.29,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-26-002054","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002054/form4.xml","form_type":"4"}},{"id":813846,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":false,"shares":157417,"price":0.07,"value":11019.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"shares","element":"transactionShares","label":"F4","text":"On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":110000,"derivative":{"exercise_price":0.07,"exercise_date":"2026-03-31","expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":156086},"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813845,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029."}],"balance_after":110000,"derivative":{"exercise_price":0.29,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813844,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":true,"shares":157417,"price":0.07,"value":11019.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":21252673,"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813843,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":21095256,"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813842,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series F Stock","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":false,"shares":10,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813841,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":true,"shares":2157,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773."}],"balance_after":21055256,"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813839,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-04-07T17:53:55.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029."}],"balance_after":110000,"derivative":{"exercise_price":0.29,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-26-002048","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002048/form4.xml","form_type":"4"}},{"id":847121,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":false,"shares":156086,"price":0.07,"value":10926.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"shares","element":"transactionShares","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":120000,"derivative":{"exercise_price":0.07,"exercise_date":"2026-02-27","expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":156086},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847120,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.2,"exercise_date":"2026-02-25","expiration_date":"2026-02-25","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847119,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":500000,"derivative":{"exercise_price":0.2,"exercise_date":"2026-02-25","expiration_date":"2026-02-25","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847118,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2022-09-01","expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847117,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":500000,"derivative":{"exercise_price":0.65,"exercise_date":"2026-02-25","expiration_date":"2027-09-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847116,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.65,"exercise_date":"2022-09-01","expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847115,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-02","kind":"exercise","planned":false,"acquired":false,"shares":312720,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"shares","element":"transactionShares","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":130000,"derivative":{"exercise_price":0.07,"exercise_date":"2026-01-30","expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":312720},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847114,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-03-12T23:52:25.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":false,"shares":195460,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"shares","element":"transactionShares","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":150000,"derivative":{"exercise_price":0.07,"exercise_date":"2025-11-28","expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":195460},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847113,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":true,"shares":156086,"price":0.07,"value":10926.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":21053099,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847112,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-27","kind":"other","planned":false,"acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":20897013,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847111,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series E Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-27","kind":"other","planned":false,"acquired":false,"shares":100,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847110,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":20497013,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847109,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-02","kind":"exercise","planned":false,"acquired":true,"shares":312720,"price":0.07,"value":21890.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":19997013,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847108,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-01-05","kind":"other","planned":false,"acquired":true,"shares":25338,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157."}],"balance_after":19684293,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847107,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":true,"shares":195460,"price":0.07,"value":13682.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":19658955,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":863237,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2026-03-04T20:44:48.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027."}],"balance_after":52778,"derivative":{"exercise_price":0.25,"exercise_date":"2026-02-25","expiration_date":"2026-02-25","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001477932-26-001162","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001162/form4.xml","form_type":"4"}},{"id":863236,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2026-03-04T20:44:48.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027."}],"balance_after":152778,"derivative":{"exercise_price":0.25,"exercise_date":"2026-02-25","expiration_date":"2026-02-25","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001477932-26-001162","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001162/form4.xml","form_type":"4"}},{"id":863235,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2026-03-04T20:44:48.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.65,"exercise_date":"2022-09-01","expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001477932-26-001162","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001162/form4.xml","form_type":"4"}},{"id":863234,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2026-03-04T20:44:48.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027."}],"balance_after":100000,"derivative":{"exercise_price":0.5,"exercise_date":"2026-02-25","expiration_date":"2027-09-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001477932-26-001162","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001162/form4.xml","form_type":"4"}},{"id":863233,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2026-03-04T20:44:48.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2022-09-01","expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001477932-26-001162","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001162/form4.xml","form_type":"4"}},{"id":863232,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-04T20:44:48.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027."}],"balance_after":653495,"source":{"system":"sec-edgar","filing":"0001477932-26-001162","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001162/form4.xml","form_type":"4"}},{"id":1047125,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53500,"kind":"person","name":"Grujic Alan","position":1,"cik":"0001980904","reported_name":"Grujic Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2025-09-05T20:25:49.000Z","date":"2025-08-29","kind":"purchase","planned":false,"acquired":true,"shares":152108,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On August 29, 2025, the Company closed on Tranche 4 Private Financing. The Company simultaneously entered into a Securities Purchase Agreement and an exchange agreement with Mr. Grujic, whereby Mr. Grujic agreed to exchange a $25,000 note payable and accrued interest of $2,379.45 for an aggregate of 152,108 units, each unit consisting of one share of common stock and one warrant to purchase up to 152,108 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance and will expire in four years following the issuance date and have an exercise price of $0.25 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On August 29, 2025, the Company closed on Tranche 4 Private Financing. The Company simultaneously entered into a Securities Purchase Agreement and an exchange agreement with Mr. Grujic, whereby Mr. Grujic agreed to exchange a $25,000 note payable and accrued interest of $2,379.45 for an aggregate of 152,108 units, each unit consisting of one share of common stock and one warrant to purchase up to 152,108 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance and will expire in four years following the issuance date and have an exercise price of $0.25 per share."}],"balance_after":177108,"derivative":{"exercise_price":0.25,"exercise_date":"2025-08-29","expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":152108},"source":{"system":"sec-edgar","filing":"0001477932-25-006531","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006531/form4.xml","form_type":"4"}},{"id":1047124,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53500,"kind":"person","name":"Grujic Alan","position":1,"cik":"0001980904","reported_name":"Grujic Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:25:49.000Z","date":"2025-08-29","kind":"purchase","planned":false,"acquired":true,"shares":152108,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On August 29, 2025, the Company closed on Tranche 4 Private Financing. The Company simultaneously entered into a Securities Purchase Agreement and an exchange agreement with Mr. Grujic, whereby Mr. Grujic agreed to exchange a $25,000 note payable and accrued interest of $2,379.45 for an aggregate of 152,108 units, each unit consisting of one share of common stock and one warrant to purchase up to 152,108 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance and will expire in four years following the issuance date and have an exercise price of $0.25 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On August 29, 2025, the Company closed on Tranche 4 Private Financing. The Company simultaneously entered into a Securities Purchase Agreement and an exchange agreement with Mr. Grujic, whereby Mr. Grujic agreed to exchange a $25,000 note payable and accrued interest of $2,379.45 for an aggregate of 152,108 units, each unit consisting of one share of common stock and one warrant to purchase up to 152,108 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance and will expire in four years following the issuance date and have an exercise price of $0.25 per share."}],"balance_after":1817541,"source":{"system":"sec-edgar","filing":"0001477932-25-006531","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006531/form4.xml","form_type":"4"}},{"id":1047123,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53500,"kind":"person","name":"Grujic Alan","position":1,"cik":"0001980904","reported_name":"Grujic Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:25:49.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 21, 2025, Mr. Grujic converted 50 shares of Series E preferred stock into 200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 21, 2025, Mr. Grujic converted 50 shares of Series E preferred stock into 200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":1665433,"source":{"system":"sec-edgar","filing":"0001477932-25-006531","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006531/form4.xml","form_type":"4"}},{"id":1047122,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53500,"kind":"person","name":"Grujic Alan","position":1,"cik":"0001980904","reported_name":"Grujic Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Preferred Series E Stock","published_at":"2025-09-05T20:25:49.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":false,"shares":50,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 21, 2025, Mr. Grujic converted 50 shares of Series E preferred stock into 200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 21, 2025, Mr. Grujic converted 50 shares of Series E preferred stock into 200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-006531","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006531/form4.xml","form_type":"4"}},{"id":1047121,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53500,"kind":"person","name":"Grujic Alan","position":1,"cik":"0001980904","reported_name":"Grujic Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:25:49.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":true,"shares":17408,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298."}],"balance_after":1465433,"source":{"system":"sec-edgar","filing":"0001477932-25-006531","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006531/form4.xml","form_type":"4"}},{"id":1047120,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-09-05T20:16:44.000Z","date":"2025-08-29","kind":"purchase","planned":false,"acquired":true,"shares":166667,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On August 29, 2025, the Company entered into a Securities Purchase Agreement with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $30,000, 166,667 units, each unit consisting of one share of common stock and one warrant to purchase up to 166,667 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.25 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On August 29, 2025, the Company entered into a Securities Purchase Agreement with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $30,000, 166,667 units, each unit consisting of one share of common stock and one warrant to purchase up to 166,667 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.25 per share."}],"balance_after":191667,"derivative":{"exercise_price":0.25,"exercise_date":"2025-08-29","expiration_date":"2029-08-29","underlying":"Common Stock","underlying_shares":166667},"source":{"system":"sec-edgar","filing":"0001477932-25-006528","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006528/form4.xml","form_type":"4"}},{"id":1047119,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:16:44.000Z","date":"2025-08-29","kind":"purchase","planned":false,"acquired":true,"shares":166667,"price":0.18,"value":30000.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On August 29, 2025, the Company entered into a Securities Purchase Agreement with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $30,000, 166,667 units, each unit consisting of one share of common stock and one warrant to purchase up to 166,667 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.25 per share."}],"balance_after":19463495,"source":{"system":"sec-edgar","filing":"0001477932-25-006528","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006528/form4.xml","form_type":"4"}},{"id":1047118,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:16:44.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":true,"shares":1200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":19296828,"source":{"system":"sec-edgar","filing":"0001477932-25-006528","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006528/form4.xml","form_type":"4"}},{"id":1047117,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series E Stock","published_at":"2025-09-05T20:16:44.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":false,"shares":300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0001477932-25-006528","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006528/form4.xml","form_type":"4"}},{"id":1047116,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:16:44.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":true,"shares":104448,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298."}],"balance_after":18096828,"source":{"system":"sec-edgar","filing":"0001477932-25-006528","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006528/form4.xml","form_type":"4"}},{"id":1047113,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2025-09-05T20:03:35.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares are subject to the award vested on June 3, 2025; the remaining shares will vest monthly, starting on September 3, 2025, subject to the reporting person's continued service on each such date, until the award is fully vested on June 2, 2028."}],"balance_after":110000,"derivative":{"exercise_price":0.14,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-25-006522","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006522/form4.xml","form_type":"4"}},{"id":1047112,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:03:35.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":true,"shares":932000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On August 21, 2025, Mr. Blumberg (WMB Pension Plan fbo Richard Blumberg) converted 233 shares of Series E preferred stock into 932,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On August 21, 2025, Mr. Blumberg (WMB Pension Plan fbo Richard Blumberg) converted 233 shares of Series E preferred stock into 932,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 exercise price."}],"balance_after":7924180,"source":{"system":"sec-edgar","filing":"0001477932-25-006522","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006522/form4.xml","form_type":"4"}},{"id":1047111,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series E Stock","published_at":"2025-09-05T20:03:35.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":false,"shares":233,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On August 21, 2025, Mr. Blumberg (WMB Pension Plan fbo Richard Blumberg) converted 233 shares of Series E preferred stock into 932,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On August 21, 2025, Mr. Blumberg (WMB Pension Plan fbo Richard Blumberg) converted 233 shares of Series E preferred stock into 932,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 exercise price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-006522","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006522/form4.xml","form_type":"4"}},{"id":1047110,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:03:35.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":true,"shares":81121,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298."}],"balance_after":6992180,"source":{"system":"sec-edgar","filing":"0001477932-25-006522","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006522/form4.xml","form_type":"4"}},{"id":1047109,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:03:35.000Z","date":"2025-04-10","kind":"other","planned":false,"acquired":true,"shares":55853,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.0943."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.0943."}],"balance_after":6911059,"source":{"system":"sec-edgar","filing":"0001477932-25-006522","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006522/form4.xml","form_type":"4"}},{"id":1047108,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:03:35.000Z","date":"2025-04-10","kind":"other","planned":false,"acquired":true,"shares":165481,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."}],"balance_after":6855206,"source":{"system":"sec-edgar","filing":"0001477932-25-006522","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006522/form4.xml","form_type":"4"}},{"id":1047115,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2025-09-05T15:50:36.000Z","date":"2025-08-29","kind":"purchase","planned":false,"acquired":true,"shares":27778,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 29, 2025, the Company entered into a Securities Purchase Agreement with Mr. James, pursuant to which the Company agreed to sell, for a total price of $5,000, an aggregate of 27,778 units, each unit consisting of one share of common stock and one warrant to purchase up to 27,778 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance and will expire in four years following the issuance date and have an exercise price of $0.25 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 29, 2025, the Company entered into a Securities Purchase Agreement with Mr. James, pursuant to which the Company agreed to sell, for a total price of $5,000, an aggregate of 27,778 units, each unit consisting of one share of common stock and one warrant to purchase up to 27,778 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance and will expire in four years following the issuance date and have an exercise price of $0.25 per share."}],"balance_after":52778,"derivative":{"exercise_price":0.25,"exercise_date":"2025-08-29","expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":27778},"source":{"system":"sec-edgar","filing":"0001477932-25-006513","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006513/form4.xml","form_type":"4"}},{"id":1047114,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T15:50:36.000Z","date":"2025-08-29","kind":"purchase","planned":false,"acquired":true,"shares":27778,"price":0.18,"value":5000.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 29, 2025, the Company entered into a Securities Purchase Agreement with Mr. James, pursuant to which the Company agreed to sell, for a total price of $5,000, an aggregate of 27,778 units, each unit consisting of one share of common stock and one warrant to purchase up to 27,778 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance and will expire in four years following the issuance date and have an exercise price of $0.25 per share."}],"balance_after":553495,"source":{"system":"sec-edgar","filing":"0001477932-25-006513","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006513/form4.xml","form_type":"4"}},{"id":1112434,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-06-13T16:10:12.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the award vested on June 3, 2025; the remaining shares will vest monthly, starting on September 3, 2025, subject to the reporting person's continued service on each such date, until the award is fully vested on June 2, 2028."}],"balance_after":110000,"derivative":{"exercise_price":0.14,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-25-004576","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004576/form4.xml","form_type":"4"}},{"id":1114134,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53500,"kind":"person","name":"Grujic Alan","position":1,"cik":"0001980904","reported_name":"Grujic Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-06-12T23:20:43.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the award vested on June 3, 2025; the remaining shares will vest monthly, starting on September 3, 2025, subject to the reporting person's continued service on each such date, until the award is fully vested on June 2, 2028."}],"balance_after":110000,"derivative":{"exercise_price":0.14,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-25-004560","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004560/form4.xml","form_type":"4"}},{"id":1114133,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-06-12T23:20:23.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the award vested on June 3, 2025; the remaining shares will vest monthly, starting on September 3, 2025, subject to the reporting person's continued service on each such date, until the award is fully vested on June 2, 2028."}],"balance_after":110000,"derivative":{"exercise_price":0.14,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-25-004559","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004559/form4.xml","form_type":"4"}},{"id":1136042,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":263069,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."}],"balance_after":1263069,"derivative":{"exercise_price":0.13,"exercise_date":"2025-03-18","expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":263069},"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136041,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."}],"balance_after":1000000,"derivative":{"exercise_price":0.13,"exercise_date":"2025-03-18","expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136040,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-04-10","kind":"other","planned":false,"acquired":true,"shares":6365,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."}],"balance_after":17992380,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136039,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":263069,"price":0.1,"value":26306.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."}],"balance_after":17986015,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136038,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":0.1,"value":100000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."}],"balance_after":17722946,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136037,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series E Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-13","kind":"purchase","planned":false,"acquired":true,"shares":150,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 13, 2025, for a purchase price of $30,000, Mr. Imhoff purchased 150 shares of Series E preferred stock from a third party. The shares have a conversion price of $0.25 and a stated value of $1,000."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 13, 2025, for a purchase price of $30,000, Mr. Imhoff purchased 150 shares of Series E preferred stock from a third party. The shares have a conversion price of $0.25 and a stated value of $1,000."}],"balance_after":400,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136036,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-11","kind":"other","planned":false,"acquired":true,"shares":2258690,"price":0.1266,"value":285950.154,"ownership":{"direct":true},"balance_after":16722946,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136035,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-11","kind":"other","planned":false,"acquired":false,"shares":286,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136034,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-07","kind":"purchase","planned":false,"acquired":true,"shares":286,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."}],"balance_after":286,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136033,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":true,"shares":4801500,"price":0.5,"value":2400750.0,"ownership":{"direct":true},"balance_after":14464256,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136032,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C2 Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":false,"shares":2400.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136031,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":true,"shares":900000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."}],"balance_after":9662756,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136030,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series D Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":false,"shares":300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1170273,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":263069,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."}],"balance_after":1263069,"derivative":{"exercise_price":0.13,"exercise_date":"2025-03-18","expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":263069},"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170272,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 18, 2025, the Company entered into a Securities Purchase Agreement (the \"March Purchase Agreement\") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the \"March Warrants\"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 18, 2025, the Company entered into a Securities Purchase Agreement (the \"March Purchase Agreement\") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the \"March Warrants\"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share."}],"balance_after":1000000,"derivative":{"exercise_price":0.13,"exercise_date":"2025-03-18","expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170271,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-04-10","kind":"other","planned":false,"acquired":true,"shares":6365,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."}],"balance_after":17992380,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170270,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":263069,"price":0.1,"value":26306.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."}],"balance_after":17986015,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170269,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":0.1,"value":100000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 18, 2025, the Company entered into a Securities Purchase Agreement (the \"March Purchase Agreement\") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the \"March Warrants\"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share."}],"balance_after":17722946,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170268,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-11","kind":"other","planned":false,"acquired":true,"shares":2258690,"price":0.1266,"value":285950.154,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."}],"balance_after":16722946,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170267,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-11","kind":"other","planned":false,"acquired":false,"shares":286,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170266,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-07","kind":"purchase","planned":false,"acquired":true,"shares":286,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."}],"balance_after":286,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170265,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":true,"shares":4801500,"price":0.5,"value":2400750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares."}],"balance_after":14464256,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170264,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C2 Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":false,"shares":2400.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170263,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":true,"shares":900000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."}],"balance_after":9662756,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170262,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series D Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":false,"shares":300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1176000,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2025-04-08T16:11:23.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":262945,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Mr. James, whereby Mr. James agreed to exchange a $25,000 note payable and accrued interest of $1,295 for 262,945 units as described above."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Mr. James, whereby Mr. James agreed to exchange a $25,000 note payable and accrued interest of $1,295 for 262,945 units as described above."}],"balance_after":412945,"derivative":{"exercise_price":0.13,"exercise_date":"2025-03-18","expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":262945},"source":{"system":"sec-edgar","filing":"0001477932-25-002516","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002516/form4.xml","form_type":"4"}},{"id":1175999,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2025-04-08T16:11:23.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2025, the Company entered into a Securities Purchase Agreement (the \"March Purchase Agreement\") with Mr. James, pursuant to which the Company agreed to sell, for a total price of $15,000, an aggregate of 150,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 150,000 shares of common stock (the \"March Warrants\"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2025, the Company entered into a Securities Purchase Agreement (the \"March Purchase Agreement\") with Mr. James, pursuant to which the Company agreed to sell, for a total price of $15,000, an aggregate of 150,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 150,000 shares of common stock (the \"March Warrants\"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share."}],"balance_after":150000,"derivative":{"exercise_price":0.13,"exercise_date":"2025-03-18","expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001477932-25-002516","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002516/form4.xml","form_type":"4"}},{"id":1175998,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T16:11:23.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":262945,"price":0.1,"value":26294.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Mr. James, whereby Mr. James agreed to exchange a $25,000 note payable and accrued interest of $1,295 for 262,945 units as described above."}],"balance_after":525717,"source":{"system":"sec-edgar","filing":"0001477932-25-002516","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002516/form4.xml","form_type":"4"}},{"id":1175997,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53499,"kind":"person","name":"JAMES MICHAEL C","position":1,"cik":"0001365831","reported_name":"JAMES MICHAEL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T16:11:23.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":150000,"price":0.1,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2025, the Company entered into a Securities Purchase Agreement (the \"March Purchase Agreement\") with Mr. James, pursuant to which the Company agreed to sell, for a total price of $15,000, an aggregate of 150,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 150,000 shares of common stock (the \"March Warrants\"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share."}],"balance_after":262772,"source":{"system":"sec-edgar","filing":"0001477932-25-002516","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002516/form4.xml","form_type":"4"}},{"id":1265000,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-18T11:04:39.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":35312,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1593."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1593."}],"balance_after":8762756,"source":{"system":"sec-edgar","filing":"0001477932-25-001072","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225001072/form4.xml","form_type":"4"}},{"id":1324684,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2024-12-20T23:29:20.000Z","date":"2024-12-18","kind":"purchase","planned":false,"acquired":true,"shares":1615385,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $210,000, the Company issued 1,615,385 shares of its common stock and warrants to purchase an aggregate of 1,615,385 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 18, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $210,000, the Company issued 1,615,385 shares of its common stock and warrants to purchase an aggregate of 1,615,385 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share."}],"balance_after":1615385,"derivative":{"exercise_price":0.18,"exercise_date":"2024-12-18","expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":1615385},"source":{"system":"sec-edgar","filing":"0001477932-24-008256","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224008256/form4.xml","form_type":"4"}},{"id":1324683,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T23:29:20.000Z","date":"2024-12-18","kind":"purchase","planned":false,"acquired":true,"shares":1615385,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 18, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $210,000, the Company issued 1,615,385 shares of its common stock and warrants to purchase an aggregate of 1,615,385 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share."}],"balance_after":8727444,"source":{"system":"sec-edgar","filing":"0001477932-24-008256","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224008256/form4.xml","form_type":"4"}},{"id":1381610,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-25T16:23:52.000Z","date":"2024-10-15","kind":"other","planned":false,"acquired":true,"shares":36161,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1556."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1556."}],"balance_after":7112059,"source":{"system":"sec-edgar","filing":"0001477932-24-006671","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224006671/form4.xml","form_type":"4"}},{"id":1382143,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2024-10-24T16:10:17.000Z","date":"2024-09-01","kind":"other","planned":false,"acquired":true,"shares":900000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The common stock and warrants from the fourth tranche were issued on September 1, 2024 and October 14, 2024, respectively."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The common stock and warrants from the fourth tranche were issued on September 1, 2024 and October 14, 2024, respectively."}],"balance_after":3600000,"derivative":{"exercise_price":0.3,"exercise_date":"2024-09-01","expiration_date":"2027-09-01","underlying":"Common shares","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001477932-24-006656","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224006656/form4.xml","form_type":"4"}},{"id":1382142,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":49758,"kind":"person","name":"Blumberg Richard P.","position":1,"cik":"0001486345","reported_name":"Blumberg Richard P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-24T16:10:17.000Z","date":"2024-10-14","kind":"other","planned":false,"acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The common stock and warrants from the fourth tranche were issued on September 1, 2024 and October 14, 2024, respectively."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The common stock and warrants from the fourth tranche were issued on September 1, 2024 and October 14, 2024, respectively."}],"balance_after":6689725,"source":{"system":"sec-edgar","filing":"0001477932-24-006656","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224006656/form4.xml","form_type":"4"}},{"id":1395471,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2024-10-02T20:30:20.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"shares":1666667,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 23, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $150,000, the Company issued 1,666,667 shares of its common stock and warrants to purchase an aggregate of 1,666,667 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.12 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $150,000, the Company issued 1,666,667 shares of its common stock and warrants to purchase an aggregate of 1,666,667 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.12 per share."}],"balance_after":1666667,"derivative":{"exercise_price":0.12,"exercise_date":"2024-09-23","expiration_date":"2028-09-22","underlying":"Common Stock","underlying_shares":1666667},"source":{"system":"sec-edgar","filing":"0001477932-24-006161","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224006161/form4.xml","form_type":"4"}}],"next_cursor":"2024-10-02T20:30:20.000000Z,1395471"}